LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Drug-Resistant Bacteria Can Raise Sepsis Risk

By LabMedica International staff writers
Posted on 11 May 2017
Image: Research shows that when drug-resistant bacteria such as e. coli enter the bloodstream, it can raise a person’s risk for sepsis (Photo courtesy of the CDC).
Image: Research shows that when drug-resistant bacteria such as e. coli enter the bloodstream, it can raise a person’s risk for sepsis (Photo courtesy of the CDC).
Sepsis affects an estimated 30 million people worldwide each year and without quick treatment, it can lead to multiple organ failure and death. Treating sepsis can be even more difficult if the bacteria responsible are resistant to antibiotics.

In some cases bacteria may be spreading from the bowel or urinary tract into the bloodstream, while in others the bacteria found in patients’ urine or stool samples could be transferring their ability to resist antibiotics to other bacteria in the body, which then can cause sepsis.

Scientists at the Karolinska Institutet studied 66,000 people and showed that the risk of drug resistant sepsis is highest soon after drug resistant bacteria have been detected in a patient’s urine or stool, and that this risk diminishes over time. They say their findings could help doctors diagnose drug resistant sepsis and inform treatment choices. The team studied all subjects who were found to have specific types of bacteria in their urine or stool samples in Sweden between 2007 and 2012, more than 22,000 in total. They compared them with an equivalent group of 44,000 people who had no diagnosis of extended-spectrum β-lactamase-producing Enterobacteriaceae (EPE).

The investigators focused on certain bacteria, such as Escherichia coli, that produce enzymes called extended spectrum β-lactamases. These enzymes allow bacteria to break down a variety of antibiotics including penicillin and third-generation cephalosporins. They followed the subjects for six years to find out if they subsequently developed a bloodstream infection. The data revealed that people whose bowels had been colonized previously by EPE were 57 times more likely to develop an EPE infection of the bloodstream, compared to the general population. For those with a previous finding of EPE in their urine, the risk was 113 times higher than the general population. Over the six-year study period, 2% of those with EPE in the bowel and 4% of those with a urinary tract infection went on to have a bloodstream infection with EPE. This compares to 0.02% in the general population.

Joakim Isendahl, MD, who presented the study said, “Knowing if a patient has had a previous finding of EPE, and how long ago it was, helps inform doctors on when last-­resort drugs are essential, but also on when they are not needed. This is important since prudent use is imperative to keep them effective. We found that the riskiest time was in the days and weeks after the bacteria were found in the urine or stool sample, but there is still an increased risk up to three years later.” The study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, held April 22-25, 2017, in Vienna, Austria.

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automatic Hematology Analyzer
DH-800 Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more